Our entrepreneurial, high-science culture in combination with our fast and nimble decision-making makes us the perfect partner for long-lasting and productive relationships.
To maximize the value of our antibody platform AbiProt® and to build on our experience of eight approved and marketed drugs, we seek collaborations with other pharmaceutical and biotechnology companies to create or co-develop antibody products for novel disease targets.
We are highly motivated to build strategic alliances that will help to improve patients’ lives by creating and developing innovative and differentiated antibody-based therapeutics.
We are always open to discuss potential collaborations.
Please contact us at: business_development@obliquet.com
